Medicenna Therapeutics Corp

MDNA

Company Profile

  • Business description

    Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

  • Contact

    2 Bloor Street West
    Suite 903
    TorontoONM4W 3E2
    CAN

    T: +1 416 964-5442

    https://www.medicenna.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 March 2026

    Employees

    17

Stocks News & Analysis

stocks

Another incredible quarter from Microsoft

We were wrong when we thought last quarter would be hard to top.
stocks

10 best US dividend aristocrats to buy now—including a surprise outperformer

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks

Leading ASX players in this field look materially overvalued

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,999.0016.40-0.18%
CAC 407,771.9789.99-1.14%
DAX 4024,065.47196.75-0.81%
Dow JONES (US)44,130.98330.30-0.74%
FTSE 1009,132.814.13-0.05%
HKSE24,773.33403.60-1.60%
NASDAQ21,122.457.23-0.03%
Nikkei 22541,069.82415.121.02%
NZX 50 Index12,823.7432.23-0.25%
S&P 5006,339.3923.51-0.37%
S&P/ASX 2008,742.8013.60-0.16%
SSE Composite Index3,573.2142.51-1.18%

Market Movers